ACRV Acrivon Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 10-K/10-Q 八月 12, 2026
$1.73
· % 处于52周区间
· 高于低点
· 至高点
$1.2752周低点
$3.5652周高点
市值 (MRQ)
$74M
P/E
-0.9
EPS
$-2.02
ACRV 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$1.73
市值 (MRQ)
$74M
P/E
-0.9
EPS
$-2.02
ROE
-61.0%
52周区间
$1–$4
ACRV 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
10年表现 收入、净利润、利润率和每股收益趋势
EPS$-2.022021-12-31 → 2025-12-31
自由现金流$-65M2022-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | ACRV | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | -0.95年均值 ≈-1.8 | ≈-1.8 | · | · | |
| 市净率 (MRQ) | 0.95年均值 ≈1.0 | ≈1.0 | 1.7 | 低估 | |
| 股价/自由现金流 (TTM) | -1.25年均值 ≈-3.6 | ≈-3.6 | · | · | |
| 市现率 (TTM) | -1.25年均值 ≈-3.8 | ≈-3.8 | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 0.55年均值 ≈1.0 | ≈1.0 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | ACRV | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| ROA | -47.8%5年均值 ≈-38.8% | ≈-38.8% | -53.1% | 顶尖 | |
| ROE | -61.0%5年均值 ≈-50.1% | ≈-50.1% | -74.9% | 顶尖 | |
| ROIC | -74.8% | · | -64.8% | 持平 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | ACRV | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 8.05年均值 ≈12.1 | ≈12.1 | 6.9 | 流动性强 | |
| Quick Ratio (速动比率) | 7.65年均值 ≈11.8 | ≈11.8 | 6.7 | 流动性强 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
资本效率 资产周转率、库存周转率、应收账款周转率
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
11.3%
下次报告
十一月 12, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 19, 2026 | $-0.43 | $-0.51 | 15.7% |
| 2026年3月31日 | 五月 20, 2026 | $-0.49 | $-0.54 | 8.6% |
| 2025年12月31日 | $-0.52 | $-0.48 | -9.3% | |
| 2025年9月30日 | $-0.47 | $-0.60 | 21.9% | |
| 2025年6月30日 | $-0.55 | $-0.60 | 8.0% | |
| 2025年3月31日 | $-0.51 | $-0.66 | 22.1% | |
| 2024年12月31日 | $-0.60 | $-0.68 | 11.9% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| R&D Expense | $60M | $64M | $46M | $24M | · | |
| SG&A Expense | $24M | $25M | $21M | $9M | · | |
| Operating Expenses | $84M | $89M | $67M | $33M | $16M | |
| Operating Income | $-84M | $-89M | $-67M | $-33M | $-16M | |
| Interest Income | · | · | $7M | $2M | · | |
| Other Non-op | $-270.0K | $-558.0K | $-322.0K | $1M | $21.0K | |
| Pretax Income | $-78M | $-80M | · | · | · | |
| Income Tax | $0 | · | · | · | · | |
| Net Income | $-78M | $-81M | $-60M | $-31M | $-16M | |
| EPS (Basic) | $-2.02 | $-2.38 | $-2.74 | $-7.56 | $-9.32 | |
| EPS (Diluted) | $-2.02 | $-2.38 | $-2.74 | $-7.56 | $-9.32 | |
| Shares (Basic) | 38,509,281 | 33,791,817 | 22,078,190 | 4,121,912 | 1,743,382 | |
| Shares (Diluted) | 38,509,281 | 33,791,817 | 22,078,190 | 4,121,912 | 1,743,382 | |
| EBITDA | $-84M | $-89M | $-67M | $-33M | · |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $40M | $36M | $30M | $100M | |
| Short-term Investments | $77M | $140M | $91M | $98M | · | |
| Prepaid Expense | $2M | $2M | $2M | $4M | $805.0K | |
| Current Assets | $120M | $182M | $130M | $132M | $100M | |
| PP&E (Net) | $5M | $4M | $3M | $2M | $290.0K | |
| PP&E (Gross) | $8M | $6M | $4M | $3M | $346.0K | |
| Accum. Depreciation | $3M | $2M | $956.0K | $420.0K | $56.0K | |
| Other Non-current Assets | $2M | $2M | $251.0K | · | · | |
| Total Assets | $130M | $197M | $138M | $181M | $107M | |
| Accounts Payable | $2M | $758.0K | $5M | $904.0K | $964.0K | |
| Current Liabilities | $16M | $17M | $13M | $7M | $3M | |
| Capital Leases | $2M | $3M | $4M | $4M | $5M | |
| Total Liabilities | $17M | $20M | $17M | $11M | $8M | |
| Common Stock | $31.0K | $31.0K | $23.0K | $22.0K | $2.0K | |
| Paid-in Capital | $387M | $373M | $238M | $227M | $1M | |
| Retained Earnings | $-275M | $-197M | $-116M | $-56M | $-25M | |
| AOCI | $111.0K | $447.0K | $-83.0K | $-95.0K | · | |
| Stockholders' Equity | $113M | $177M | $121M | $170M | $-24M | |
| Liabilities + Equity | $130M | $197M | $138M | $181M | $107M | |
| Shares Outstanding | 31,648,856 | 31,231,264 | 22,522,644 | 21,920,402 | 1,769,561 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Stock-based Comp | $15M | $14M | $12M | $2M | $497.0K | |
| Operating Cash Flow | $-64M | $-66M | $-43M | $-30M | $-14M | |
| CapEx | $2M | $3M | $1M | $2M | $238.0K | |
| Investing Cash Flow | $66M | $-52M | $51M | $-142M | $-238.0K | |
| Financing Cash Flow | $-749.0K | $121M | $-2M | $102M | $112M | |
| Net Change in Cash | $2M | $4M | $7M | $-70M | $98M | |
| Free Cash Flow | $-65M | $-68M | $-44M | $-32M | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| ROA | -47.8% | -48.1% | -37.8% | -21.7% | · | |
| ROE | -61.0% | -43.1% | -46.6% | -49.9% | · | |
| ROIC | -74.8% | · | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 7.7 | 10.6 | 9.7 | 20.3 | · | |
| Quick Ratio | 7.6 | 10.4 | 9.6 | 19.6 | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Book Value / Share | $3.56 | $5.66 | $5.38 | $7.78 | · | |
| Cash Flow / Share | $-1.65 | $-1.94 | $-1.93 | $-7.31 | · | |
| Cash / Share | $1.31 | $1.27 | $1.60 | $1.35 | · | |
| EPS (TTM) | $-2.02 | $-2.38 | $-2.74 | $-7.56 | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Net Income TTM | $-78M | $-81M | $-60M | $-31M | · | |
| Market Cap | $76M | $188M | $111M | $253M | · | |
| P/E | -1.2 | -2.5 | -1.8 | -1.5 | · | |
| P/B | 0.7 | 1.1 | 0.9 | 1.5 | · | |
| P / Tangible Book | 0.7 | 1.1 | 0.9 | 1.5 | · | |
| P / Cash Flow | -1.2 | -2.9 | -2.6 | -8.4 | · | |
| P / FCF | -1.2 | -2.7 | -2.5 | -7.8 | · | |
| Earnings Yield | -83.8% | -39.5% | -55.7% | -65.6% | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $14M | $15M | $15M | $14M | $16M | $15M | $19M | $19M | $15M | $11M | $15M | $10M | $11M | $10M | · | · | |
| SG&A Expense | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $5M | $5M | · | · | |
| Operating Expenses | $19M | $20M | $20M | $20M | $23M | $22M | $25M | $25M | $21M | $18M | $21M | $16M | $16M | $14M | $10M | $10M | |
| Operating Income | $-19M | $-20M | $-20M | $-20M | $-23M | $-22M | $-25M | $-25M | $-21M | $-18M | $-21M | $-16M | $-16M | $-14M | $-10M | $-10M | |
| Other Non-op | $-156.0K | $-129.0K | $-116.0K | $-53.0K | $-87.0K | $-14.0K | $-240.0K | $1.0K | $-55.0K | $-264.0K | $109.0K | $-97.0K | $-164.0K | $-170.0K | $1M | $377.0K | |
| Net Income | $-18M | $-19M | $-19M | $-18M | $-21M | $-20M | $-23M | $-22M | $-19M | $-16M | $-19M | $-14M | $-14M | $-13M | $-9M | $-9M | |
| EPS (Basic) | $-0.43 | $-0.49 | $-0.49 | $-0.47 | $-0.55 | $-0.51 | $-0.54 | $-0.59 | $-0.52 | $-0.73 | $-0.87 | $-0.66 | $-0.63 | $-0.58 | $4.98 | $-5.17 | |
| EPS (Diluted) | $-0.43 | $-0.49 | $-0.49 | $-0.47 | $-0.55 | $-0.51 | $-0.54 | $-0.59 | $-0.52 | $-0.73 | $-0.87 | $-0.66 | $-0.63 | $-0.58 | $4.98 | $-5.17 | |
| Shares (Basic) | 41,841,887 | 38,724,803 | · | 38,560,464 | 38,461,619 | 38,350,444 | · | 38,105,131 | 36,132,616 | 22,590,804 | · | 22,081,162 | 21,971,032 | 21,920,570 | · | 1,778,255 | |
| Shares (Diluted) | 41,841,887 | 38,724,803 | · | 38,560,464 | 38,461,619 | 38,350,444 | · | 38,105,131 | 36,132,616 | 22,590,804 | · | 22,081,162 | 21,971,032 | 21,920,570 | · | 1,778,255 | |
| EBITDA | $-19M | $-20M | · | $-20M | $-23M | $-22M | · | $-25M | $-21M | $-18M | · | $-16M | $-16M | $-14M | · | $-10M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $34M | $41M | $35M | $42M | $39M | $40M | $43M | $46M | $25M | $36M | $30M | $38M | $27M | $30M | $32M | |
| Short-term Investments | $49M | $64M | $77M | $94M | $96M | $110M | $140M | $144M | $135M | $85M | $91M | $112M | $113M | $93M | $98M | · | |
| Prepaid Expense | $2M | $1M | $2M | $1M | $989.0K | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $4M | $4M | $2M | |
| Current Assets | $91M | $99M | $120M | $130M | $138M | $151M | $182M | $189M | $182M | $112M | $130M | $144M | $153M | $124M | $132M | $79M | |
| PP&E (Net) | $4M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | $8M | $8M | $8M | $8M | $8M | $7M | $6M | $6M | $5M | $5M | $4M | $3M | $3M | $3M | $3M | $2M | |
| Accum. Depreciation | $4M | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $1M | $956.0K | $807.0K | $674.0K | $545.0K | $420.0K | $295.0K | |
| Other Non-current Assets | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | · | · | $251.0K | · | · | · | · | · | |
| Total Assets | $99M | $108M | $130M | $145M | $159M | $176M | $197M | $215M | $231M | $121M | $138M | $151M | $160M | $170M | $181M | $88M | |
| Accounts Payable | $861.0K | $1M | $2M | $996.0K | $1M | $4M | $758.0K | $2M | $1M | $2M | $5M | $2M | $1M | $1M | $904.0K | $2M | |
| Current Liabilities | $11M | $11M | $16M | $15M | $13M | $14M | $17M | $15M | $11M | $9M | $13M | $9M | $7M | $6M | $7M | $6M | |
| Capital Leases | $980.0K | $1M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | |
| Total Liabilities | $12M | $12M | $17M | $17M | $16M | $16M | $20M | $18M | $15M | $13M | $17M | $13M | $11M | $10M | $11M | $11M | |
| Common Stock | $42.0K | $38.0K | $31.0K | $31.0K | $31.0K | $31.0K | $31.0K | $31.0K | $31.0K | $23.0K | $23.0K | $22.0K | $22.0K | $22.0K | $22.0K | $2.0K | |
| Paid-in Capital | $399M | $389M | $387M | $384M | $381M | $377M | $373M | $370M | $368M | $241M | $238M | $236M | $232M | $229M | $227M | $2M | |
| Retained Earnings | $-312M | $-294M | $-275M | $-256M | $-238M | $-217M | $-197M | $-174M | $-152M | $-133M | $-116M | $-97M | $-83M | $-69M | $-56M | $-47M | |
| AOCI | $-33.0K | $4.0K | $111.0K | $112.0K | $106.0K | $283.0K | $447.0K | $782.0K | $-19.0K | $-70.0K | $-83.0K | $-302.0K | $-427.0K | $9.0K | $-95.0K | $-133.0K | |
| Stockholders' Equity | $87M | $96M | $113M | $129M | $143M | $160M | $177M | $197M | $216M | $108M | $121M | $138M | $149M | $160M | $170M | $-46M | |
| Liabilities + Equity | $99M | $108M | $130M | $145M | $159M | $176M | $197M | $215M | $231M | $121M | $138M | $151M | $160M | $170M | $181M | $88M | |
| Shares Outstanding | 42,847,215 | 38,745,032 | 31,648,856 | 31,549,770 | 31,449,744 | 31,352,067 | 31,231,264 | 31,130,892 | 30,966,255 | 22,637,539 | 22,522,644 | 22,104,469 | 22,068,660 | 21,920,634 | 21,920,402 | 1,794,600 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $3M | $3M | $2M | $267.0K | |
| Operating Cash Flow | $-15M | $-21M | $-15M | $-12M | $-17M | $-20M | $-17M | $-17M | $-14M | $-17M | $-12M | $-10M | $-9M | $-11M | $-9M | $-7M | |
| CapEx | $87.0K | $14.0K | $219.0K | $899.0K | $493.0K | $58.0K | $827.0K | $989.0K | $137.0K | $815.0K | $1M | $0 | $112.0K | $25.0K | $251.0K | $426.0K | |
| Investing Cash Flow | $15M | $13M | $22M | $6M | $19M | $19M | $14M | $16M | $-88M | $6M | $21M | $2M | $19M | $9M | $-95M | $-45M | |
| Financing Cash Flow | $7M | $-33.0K | $-192.0K | $-117.0K | $-97.0K | $-343.0K | $-647.0K | $-2M | $123M | $-172.0K | $-2M | $78.0K | · | · | $102M | $-140.0K | |
| Net Change in Cash | $7M | $-7M | $6M | $-6M | $3M | $-664.0K | $-4M | $-3M | $21M | $-11M | $6M | $-8M | $11M | $-2M | $-3M | $-52M | |
| Free Cash Flow | · | $-21M | · | · | · | $-20M | · | · | · | $-18M | · | · | · | $-11M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -13.9% | -13.4% | · | -10.1% | -10.8% | -13.3% | · | -12.3% | -9.6% | -11.3% | · | -12.1% | -17.4% | -15.0% | · | -21.0% | |
| ROE | -15.6% | -14.9% | · | -11.2% | -11.7% | -14.7% | · | -13.4% | -10.3% | -12.3% | · | -31.3% | -18.6% | -15.9% | · | 40.3% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.0 | 9.0 | · | 8.8 | 10.3 | 11.2 | · | 12.8 | 16.2 | 12.4 | · | 15.5 | 21.8 | 21.8 | · | 12.3 | |
| Quick Ratio | 7.9 | 8.8 | · | 8.7 | 10.2 | 11.0 | · | 12.6 | 16.0 | 12.2 | · | 15.3 | 21.5 | 21.2 | · | 5.0 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.02 | $2.47 | · | $4.08 | $4.55 | $5.12 | · | $6.32 | $6.98 | $4.77 | · | $6.25 | $6.76 | $7.32 | · | $-25.42 | |
| Cash Flow / Share | · | $-0.53 | · | · | · | $-0.51 | · | · | · | $-0.76 | · | · | · | $-0.52 | · | · | |
| Cash / Share | $0.97 | $0.88 | · | $1.12 | $1.33 | $1.25 | · | $1.39 | $1.49 | $1.09 | · | $1.35 | $1.73 | $1.25 | · | $17.88 | |
| EPS (TTM) | $-1.88 | $-2.00 | · | $-2.07 | $-2.19 | $-2.16 | · | $-2.71 | $-2.78 | $-2.89 | · | $3.11 | $-1.40 | $-4.06 | · | $-15.00 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-74M | $-77M | · | $-82M | $-86M | $-84M | · | $-77M | $-69M | $-64M | · | $-50M | $-45M | $-37M | · | $-27M | |
| Market Cap | $76M | $54M | · | $57M | $37M | $64M | · | $218M | $180M | $162M | · | $211M | $286M | $278M | · | · | |
| P/E | -0.9 | -0.7 | · | -0.9 | -0.5 | -0.9 | · | -2.6 | -2.1 | -2.5 | · | 3.1 | -9.3 | -3.1 | · | · | |
| P/B | 0.9 | 0.6 | · | 0.4 | 0.3 | 0.4 | · | 1.1 | 0.8 | 1.5 | · | 1.5 | 1.9 | 1.7 | · | · | |
| P / Tangible Book | 0.9 | 0.6 | · | 0.4 | 0.3 | 0.4 | · | 1.1 | 0.8 | 1.5 | · | 1.5 | 1.9 | 1.7 | · | · | |
| P / Cash Flow | · | -2.6 | · | · | · | -3.3 | · | · | · | -9.5 | · | · | · | -24.5 | · | · | |
| Earnings Yield | -105.6% | -143.9% | · | -114.4% | -184.0% | -106.4% | · | -38.7% | -47.9% | -40.4% | · | 32.5% | -10.8% | -32.0% | · | · |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 净收入 | $-78M | $-81M | $-60M | $-31M | $-16M |
| 稀释后每股收益 (EPS) | $-2.02 | $-2.38 | $-2.74 | $-7.56 | $-9.32 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 流动比率 | 7.7 | 10.6 | 9.7 | 20.3 | · |
| 速动比率 | 7.6 | 10.4 | 9.6 | 19.6 | · |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $-65M | $-68M | $-44M | $-32M | · |
机构持有人 (13F) 48 家申报者 · $38.1M 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
48
持有价值
$38.1M
新仓位
6
已退出持仓
4
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 6 (-4 与上一季度对比) | 4 (-8 与上一季度对比) | 21 (+10 与上一季度对比) | 9 (-2 与上一季度对比) | +5.2M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P. ×5 申报 | 2026年4月23日 | 28.80% | 修订 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 18 位内幕人士 · 10 位高管 · 8 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Peter Blume-Jensen | President and CEO | 2024年8月14日 F | 2502129 | 0 | 0 | $0 |
| Rasmus Holm-Jorgensen | Chief Financial Officer | 2025年3月1日 A | 26088 | 0 | 0 | $0 |
| Eric Devroe | Chief Operating Officer | 2026年8月18日 S | 146349 | 1 | 1 | $15986 |
| Mary Miller | Chief Legal Officer | 2026年10月5日 S | 81715 | 0 | 3 | $-1965 |
| Michaela Levin | Chief Business Officer | 2026年8月31日 A | 30000 | 0 | 0 | $0 |
| Katharine Peterson | Chief Accounting Officer | 2026年8月18日 S | 18033 | 0 | 1 | $-203 |
| Erick Gamelin | Chief Development Officer | 2026年8月18日 S | 52592 | 0 | 1 | $-804 |
| Mansoor Raza Mirza | Chief Medical Officer | 2026年5月18日 A | 38817 | 0 | 0 | $0 |
| Jean-Marie Cuillerot | Chief Medical Officer | 2025年3月1日 A | · | 0 | 0 | $0 |
| Kristina Masson | EVP - Business Operations | 2024年8月14日 F | 317246 | 0 | 0 | $0 |
| Santhosh Palani | 董事 | 2026年6月17日 A | 9366 | 0 | 0 | $0 |
| Derek Dirocco | 董事 | 2026年6月17日 A | 9366 | 0 | 0 | $0 |
| Sharon Shacham | 董事 | 2026年6月17日 A | 9366 | 0 | 0 | $0 |
| Charles M Baum | 董事 | 2026年6月17日 A | 9366 | 0 | 0 | $0 |
| Michael John Tomsicek | 董事 | 2026年6月17日 A | 9366 | 0 | 0 | $0 |
| Ivana Magovcevic-Liebisch | 董事 | 2026年6月17日 A | 9366 | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% 所有者 | 2022年11月17日 C | 888130 | 0 | 0 | $0 |
| Adam D. Levy | · | 2026年8月4日 S | 66008 | 1 | 1 | $13221 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 3 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
ACRV 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 13 位分析师
买入
中位数目标
$10.50
+506.9%
4 30.8%
强烈买入
8 61.5%
买入
1 7.7%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
6 位分析师 · 2026-10-24平均目标 $11.50 +564.7%
← 低于所有目标
当前价格 $1.73
最低$7.00
平均值$11.50
最高$19.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| ACRV | $76M | -1.2 | · | · | -61.0% | · |
| SERA | · | -4.4 | 5.2% | -39417.3% | -39.0% | · |
| CRBP | $143M | -1.4 | · | · | -60.8% | · |
| EQ | $95M | -4.0 | 13.9% | · | -133.1% | · |
| GRML | · | · | · | · | -104.9% | · |
| MNOV | $64M | -5.5 | · | -2928.8% | -27.1% | · |
| CRDF | $192M | -4.1 | -13.2% | -7732.0% | -88.2% | · |
| APLM | · | -2.5 | · | -128.7% | -1305.4% | · |
| SPRO | $131M | 15.5 | 39.2% | 12.8% | 18.7% | · |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 12, 2026 申报